Underutilized Pharma Services And Execution Risks Will Threaten Demand Yet Efficiency Will Emerge

AN

AnalystLowTarget

Not Invested

Community Contributor

Published

07 Aug 25

Updated

03 Apr 26

Views

10

03 Apr

US$10.49

AnalystLowTarget's Fair Value

US$13.00

19.3% undervalued

1Y

50.1%

7D

-8.3%

Loading

1Y

50.1%

7D

-8.3%

You can edit this narrative until Apr 4 5:10 AM. Then, changes will post as Updates.

Author's Valuation

US$1319.3% undervalued

AnalystLowTarget Fair Value

Shared on 03 Apr 26

Fair value Increased 8.33%

NEO: Expanded Genomic Test Coverage Will Support Stronger Outlook For 2026

Analysts have raised their price target on NeoGenomics from $12.00 to $13.00, citing updated assumptions for growth, profitability, discount rate, and a higher future P/E multiple. What's in the News PanTracer LBx liquid biopsy test received coverage from the Centers for Medicare & Medicaid Services’ MolDX program under LCD L38043, expanding access for Medicare patients to blood based comprehensive genomic profiling across more than 500 genes with a seven day turnaround (Key Developments).

1 view

Shared on 05 Feb 26

Fair value Increased 85%

NEO: Fair Outlook Balances Leadership Transition Patent Win And Clinical Data

Narrative Update on NeoGenomics Analysts have lifted their implied fair value estimate for NeoGenomics to US$12.00 per share, citing updated assumptions around revenue growth, discount rate, profit margin and future P/E as the key drivers behind the new price target framework. What’s in the News NeoGenomics announced a CFO succession plan, with Abhishek Jain joining as Executive Vice President on January 12, 2026 and scheduled to become CFO on March 2, 2026, as current CFO Jeff Sherman transitions toward retirement on April 14, 2026, after completing the fiscal 2025 reporting cycle.

2 views

Valuator

Company Info

Notes

AnalystLowTarget Fair Value

US$13

19.3% undervalued

Future estimation in

Revenue

Profit Margin

Future PE

Est. Revenue

$

Forecast revenue growth rate

8.54%

Historical revenue growth rate

10.19%

Healthcare Services revenue growth rate

0.20%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.13%

Calculation

US$49.23m

Earnings '29

x

43.00x

PE Ratio '29

=

US$2.12b

Market Cap '29

US$2.12b

Market Cap '29

/

133.22m

No. shares '29

=

US$15.89

Share Price '29

US$15.89 Share Price '29

Discounted to 2026 @ 6.98% p.a.

=

US$12.98

Fair Value '26